Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYK-461 in Hypertrophic Cardiomyopathy
NCT02329184Phase 1Completed
- Sponsor
- MyoKardia
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoint: Incidence of adverse events at 28 Days. Started Dec 2014; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02329184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329184.